Acute lymphoblastic leukaemia is most common cancer worldwide. NHS blood and transplant laboratories perform over 3000 procedures for transplant patients annually. About 70% of all deaths occur from cancer in developing countries and middle-class population owing to unhealthy lifestyle. Furthermore in 2018, lung, liver, stomach, colorectal and prostate cancers killed more men comparatively other cancers in 2018. Increasing incidences of cancer is driving the growth of cancer stem cell market.
Increasing prevalence of cancer in women is driving the growth of the market. As per the World Health Organization (WHO), breast, lung, colorectal, cervical and stomach cancers have killed more women than other types of cancers in 2018.
The global cancer stem cell market is segmented by mode of action and application.
Based on the mode of action, market is segmented into targeted cancerous stem cells and stem cell-based cancer therapy. Based on mode of action autologous transplant stem cell-based cancer therapy is expected to grow owing to advantages of autologous transplant, affordability, improved survival rate of patients, and increase in transplantation procedures.
Based on application, the market is segmented into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, and others. Based on the application, breast cancer is expected to be leading segment during forecast period.
Geographically, global cancer stem cell market is divided into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America and Middle East & Africa (LAMEA).
North America is likely to holds the largest market share in the global cancer stem cell market. According to the American Society of Cancer during (2006—2015), approximately 1,762,450 new cancer cases of cancer diagnosed and around 606,880 deaths from cancer are expected to occur in the US in 2019. Furthermore, during (2006 – 2015), rate of new incidence of cancer decreased by 2% per year in men and stayed about the same in women.
Europe is expected to be the second leading region in the global cancer stem cell market in the coming years. Increasing prevalence of breast cancer in U.K, and over 55,000 women was diagnosed with breast cancer each year in the UK. Rising cases of breast cancer owing to adoption of unhealthy life such less physically activity, increasing alcohol consumption, and obesity is driving the growth of the cancer stem cell market.
Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period 2019–2026. Breast cancer is widely spread in Asian countries owing to unhealthy lifestyle, increasing obesity is increasing demand of cancer stem cell market in the future. Similarly, increasing prevalence of kidney, intestine and prostate cancer in geriatric population is driving the growth in future.
LAMEA is expected to witness sluggish growth in the global market during the forecast period. This is attributed to the poor healthcare infrastructure in Africa and slow growing economies. However, growing urbanization, improving healthcare infrastructure, and high disposable income in the Middle East are projected to drive the growth.
The some of the key players in cancer stem market include AbbVie, Inc., Thermo Fisher Scientific, Inc., Bionomics; Lonza, Merck KGaA, Stemline Therapeutics, Inc., Miltenyi Biotec, MacroGenics, Inc., Irvine Scientific, OncoMed Pharmaceuticals, Inc., STEMCELL Technologies Inc., BIOTIME, INC, Sino Biological Inc., and PromoCell GmbH.
Cancer Stem Cell Market Segmentation
By Mode of Action